ALX Oncology (ALXO) News Today $1.22 +0.01 (+0.83%) (As of 10:25 AM ET) Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street TipRanks The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 February 2022 January 2022 December 2021 Time Period ALX Oncology FY2024 EPS Forecast Lifted by Cantor FitzgeraldNovember 17, 2024 | americanbankingnews.comALX Oncology Holdings Inc. (NASDAQ:ALXO) Sees Significant Decrease in Short InterestALX Oncology Holdings Inc. (NASDAQ:ALXO - Get Free Report) was the recipient of a large decrease in short interest in October. As of October 31st, there was short interest totalling 7,840,000 shares, a decrease of 18.2% from the October 15th total of 9,590,000 shares. Currently, 25.9% of the shares of the stock are sold short. Based on an average daily volume of 701,400 shares, the days-to-cover ratio is presently 11.2 days.November 15, 2024 | marketbeat.comCantor Fitzgerald Comments on ALX Oncology FY2024 EarningsALX Oncology Holdings Inc. (NASDAQ:ALXO - Free Report) - Stock analysts at Cantor Fitzgerald raised their FY2024 earnings per share estimates for ALX Oncology in a report released on Tuesday, November 12th. Cantor Fitzgerald analyst L. Watsek now forecasts that the company will post earnings perNovember 15, 2024 | marketbeat.comALX Oncology appoints Alan Sandler as CMONovember 15, 2024 | markets.businessinsider.comALX Oncology Strengthens Leadership with Key AppointmentNovember 15, 2024 | markets.businessinsider.comALX Oncology Appoints Alan Sandler, M.D., as Chief Medical OfficerNovember 14, 2024 | globenewswire.comALX Oncology Holdings: Hold Rating Amid Uncertainties and Upcoming CatalystsNovember 12, 2024 | markets.businessinsider.comCantor Fitzgerald Reiterates Overweight Rating for ALX Oncology (NASDAQ:ALXO)Cantor Fitzgerald reissued an "overweight" rating on shares of ALX Oncology in a research report on Tuesday.November 12, 2024 | marketbeat.comAnalysts Offer Predictions for ALX Oncology FY2028 EarningsALX Oncology Holdings Inc. (NASDAQ:ALXO - Free Report) - Research analysts at HC Wainwright lowered their FY2028 earnings estimates for ALX Oncology in a report released on Friday, November 8th. HC Wainwright analyst S. Ramakanth now forecasts that the company will earn $1.43 per share for the yeNovember 11, 2024 | marketbeat.comALX Oncology reports Q3 EPS (58c) consensus (78c)November 7, 2024 | markets.businessinsider.comALX Oncology Reports Third Quarter 2024 Financial Results and Provides Corporate UpdateNovember 7, 2024 | globenewswire.comALX Oncology Holdings Inc. (NASDAQ:ALXO) Given Average Rating of "Moderate Buy" by AnalystsALX Oncology Holdings Inc. (NASDAQ:ALXO - Get Free Report) has been given a consensus recommendation of "Moderate Buy" by the six analysts that are covering the stock, MarketBeat.com reports. Two research analysts have rated the stock with a hold recommendation and four have assigned a buy recommeNovember 3, 2024 | marketbeat.comALX Oncology Announces Results from Phase 1b/2 Trial of Evorpacept in Combination with Zanidatamab will be Presented at the San Antonio Breast Cancer Symposium (SABCS) 2024November 1, 2024 | globenewswire.comShort Interest in ALX Oncology Holdings Inc. (NASDAQ:ALXO) Declines By 6.7%ALX Oncology Holdings Inc. (NASDAQ:ALXO - Get Free Report) was the recipient of a large decline in short interest during the month of September. As of September 30th, there was short interest totalling 9,320,000 shares, a decline of 6.7% from the September 15th total of 9,990,000 shares. Approximately 30.9% of the company's stock are short sold. Based on an average daily trading volume, of 1,150,000 shares, the short-interest ratio is presently 8.1 days.October 16, 2024 | marketbeat.comAurora lightshow continues into the weekend across CanadaOctober 11, 2024 | ca.news.yahoo.comMillennium Management LLC Reduces Stake in ALX Oncology Holdings IncOctober 11, 2024 | finance.yahoo.comALX Oncology Holdings Inc. (NASDAQ:ALXO) Receives Consensus Rating of "Moderate Buy" from AnalystsALX Oncology Holdings Inc. (NASDAQ:ALXO - Get Free Report) has earned a consensus recommendation of "Moderate Buy" from the seven analysts that are presently covering the company, MarketBeat Ratings reports. Two analysts have rated the stock with a hold rating and five have given a buy rating to tOctober 9, 2024 | marketbeat.comALX Oncology Holdings (NASDAQ:ALXO) Stock, Short Interest ReportOctober 6, 2024 | benzinga.comALX Oncology Chief Medical Officer Sophia Randolph Resigns >ALXOOctober 4, 2024 | marketwatch.comPoint72 Asset Management L.P. Makes New $1.83 Million Investment in ALX Oncology Holdings Inc. (NASDAQ:ALXO)Point72 Asset Management L.P. acquired a new position in shares of ALX Oncology Holdings Inc. (NASDAQ:ALXO - Free Report) in the 2nd quarter, according to its most recent filing with the SEC. The fund acquired 304,100 shares of the company's stock, valued at approximately $1,834,000. Point72 AssetOctober 4, 2024 | marketbeat.comMarshall Wace LLP Has $3.83 Million Stake in ALX Oncology Holdings Inc. (NASDAQ:ALXO)Marshall Wace LLP increased its stake in ALX Oncology Holdings Inc. (NASDAQ:ALXO - Free Report) by 423.0% in the 2nd quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 635,679 shares of the company's stock after acquirinOctober 3, 2024 | marketbeat.comInvestors Balance Rate Elation Against Economic WorriesSeptember 21, 2024 | seekingalpha.comALX Oncology Holdings Inc. (NASDAQ:ALXO) Sees Large Increase in Short InterestALX Oncology Holdings Inc. (NASDAQ:ALXO - Get Free Report) saw a large increase in short interest in the month of August. As of August 31st, there was short interest totalling 9,980,000 shares, an increase of 7.5% from the August 15th total of 9,280,000 shares. Based on an average daily volume of 1,280,000 shares, the days-to-cover ratio is presently 7.8 days. Approximately 33.0% of the shares of the company are short sold.September 17, 2024 | marketbeat.comALX Oncology's Evorpacept Gains Momentum With FDA Fast Track DesignationsSeptember 12, 2024 | seekingalpha.comALX Oncology to Present at the 2024 Cantor Fitzgerald Global Healthcare ConferenceSeptember 9, 2024 | finance.yahoo.comALX Oncology Announces First Patients Dosed with Evorpacept and Sarclisa As Part of Randomized Phase 1/2 UMBRELLA Study with SanofiSeptember 4, 2024 | finance.yahoo.com396,966 Shares in ALX Oncology Holdings Inc. (NASDAQ:ALXO) Acquired by Privium Fund Management B.V.Privium Fund Management B.V. bought a new position in shares of ALX Oncology Holdings Inc. (NASDAQ:ALXO - Free Report) in the 2nd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund bought 396,966 shares of the company's stock,September 1, 2024 | marketbeat.comALX Oncology Holdings Inc. (NASDAQ:ALXO) Receives Average Rating of "Moderate Buy" from AnalystsShares of ALX Oncology Holdings Inc. (NASDAQ:ALXO - Get Free Report) have earned an average recommendation of "Moderate Buy" from the seven ratings firms that are currently covering the firm, Marketbeat Ratings reports. Two investment analysts have rated the stock with a hold rating and five have aAugust 20, 2024 | marketbeat.comALX Oncology Holdings Inc. (NASDAQ:ALXO) Sees Significant Growth in Short InterestALX Oncology Holdings Inc. (NASDAQ:ALXO - Get Free Report) was the target of a significant increase in short interest during the month of July. As of July 31st, there was short interest totalling 9,080,000 shares, an increase of 17.2% from the July 15th total of 7,750,000 shares. Based on an average daily volume of 1,280,000 shares, the days-to-cover ratio is presently 7.1 days. Approximately 30.5% of the company's shares are short sold.August 17, 2024 | marketbeat.comALX Oncology (NASDAQ:ALXO) Price Target Cut to $4.00UBS Group dropped their price objective on shares of ALX Oncology from $25.00 to $4.00 and set a "buy" rating on the stock in a research note on Friday.August 16, 2024 | marketbeat.comMaintaining Buy Rating on ALX Oncology: Promising Clinical Data and Anticipated Progress of EvorpaceptAugust 14, 2024 | markets.businessinsider.comCantor Fitzgerald Reaffirms "Overweight" Rating for ALX Oncology (NASDAQ:ALXO)Cantor Fitzgerald reiterated an "overweight" rating on shares of ALX Oncology in a research report on Monday.August 12, 2024 | marketbeat.comALX Oncology (NASDAQ:ALXO) Releases Earnings Results, Beats Estimates By $0.01 EPSALX Oncology (NASDAQ:ALXO - Get Free Report) issued its quarterly earnings data on Thursday. The company reported ($0.76) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.77) by $0.01.August 10, 2024 | marketbeat.comALX Oncology Reports Second Quarter 2024 Financial Results and Provides Corporate UpdateAugust 9, 2024 | markets.businessinsider.comALX Oncology (NASDAQ:ALXO) Receives Hold Rating from Stifel NicolausStifel Nicolaus reissued a "hold" rating and issued a $3.00 target price (down from $5.00) on shares of ALX Oncology in a report on Friday.August 9, 2024 | marketbeat.comALXO Stock Earnings: ALX Oncology Holdings Beats EPS for Q2 2024August 9, 2024 | investorplace.comPrice T Rowe Associates Inc. MD Cuts Position in ALX Oncology Holdings Inc. (NASDAQ:ALXO)Price T Rowe Associates Inc. MD decreased its holdings in ALX Oncology Holdings Inc. (NASDAQ:ALXO - Free Report) by 57.2% in the 1st quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 232,769 shares of the company's stock after selling 310,474 sharAugust 7, 2024 | marketbeat.comALX Oncology Appoints Alan Sandler, M.D., to Board of DirectorsAugust 6, 2024 | globenewswire.comLifesci Capital Comments on ALX Oncology Holdings Inc.'s Q2 2024 Earnings (NASDAQ:ALXO)ALX Oncology Holdings Inc. (NASDAQ:ALXO - Free Report) - Stock analysts at Lifesci Capital reduced their Q2 2024 earnings per share (EPS) estimates for shares of ALX Oncology in a report issued on Wednesday, July 31st. Lifesci Capital analyst S. Slutsky now forecasts that the company will earn ($August 5, 2024 | marketbeat.comALX Oncology (NASDAQ:ALXO) Downgraded by Lifesci CapitalLifesci Capital downgraded ALX Oncology from a "strong-buy" rating to a "hold" rating in a research note on Wednesday.August 2, 2024 | marketbeat.comWhy Carvana Shares Are Trading Higher By 13%; Here Are 20 Stocks Moving PremarketAugust 1, 2024 | msn.comCrude Oil Moves Lower; Moderna Shares PlungeAugust 1, 2024 | msn.comNasdaq Surges 1%; Meta Posts Upbeat EarningsAugust 1, 2024 | msn.comALX Oncology’s evorpacept shows potential in Phase II gastric cancer trialAugust 1, 2024 | finance.yahoo.comImmuno-Oncology Focused ALX Oncology Stock Falls On Updated Data From Mid-Stage Evorpacept Combo Study In Gastric Cancer PatientsAugust 1, 2024 | msn.comStifel Nicolaus Cuts ALX Oncology (NASDAQ:ALXO) Price Target to $5.00Stifel Nicolaus dropped their price objective on ALX Oncology from $14.00 to $5.00 and set a "hold" rating for the company in a research note on Thursday.August 1, 2024 | marketbeat.comALX Oncology (NASDAQ:ALXO) Earns "Buy" Rating from HC WainwrightHC Wainwright reiterated a "buy" rating and set a $25.00 price objective on shares of ALX Oncology in a research note on Thursday.August 1, 2024 | marketbeat.comALX Oncology: Phase 2 Data Shows Evorpacept Enhances Tumor Response In HER2-Positive Gastric CancerAugust 1, 2024 | markets.businessinsider.comALX Oncology Reports Topline Data From ASPEN-06 Phase 2 Trial Demonstrating Evorpacept Improves Tumor Response in Patients With HER2-Positive Gastric CancerJuly 31, 2024 | globenewswire.comALX Oncology to Host Investor Call and Webcast to Share Topline Data Results From ASPEN-06 Phase 2 Clinical Trial of Evorpacept for the Treatment of Advanced HER2-Positive Gastric CancerJuly 31, 2024 | globenewswire.com Get ALX Oncology News Delivered to You Automatically Sign up to receive the latest news and ratings for ALXO and its competitors with MarketBeat's FREE daily newsletter. Email Address Download Our Tesla Ebook For Free (Ad)Like many of you, we here at the TradingPub are bullish on Tesla long term. We believe the company will continue to be a leader in technology, EVs and A.I. We also believe it’s share price will be rewarded in a big way… In fact, our #1 Tesla expert just published a brand new Ebook regarding Tesla’s future, and we’d like to send it to you at no cost. To claim your copy free of charge simply follow this link. ALXO Media Mentions By Week ALXO Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. ALXO News Sentiment▼0.510.46▲Average Medical News Sentiment ALXO News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. ALXO Articles This Week▼92▲ALXO Articles Average Week Get ALX Oncology News Delivered to You Automatically Sign up to receive the latest news and ratings for ALXO and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies Atyr PHARMA News Today Fate Therapeutics News Today Benitec Biopharma News Today Aurora Cannabis News Today Neurogene News Today Biomea Fusion News Today Molecular Partners News Today Cybin News Today Zentalis Pharmaceuticals News Today Genfit News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:ALXO) was last updated on 11/21/2024 by MarketBeat.com Staff From Our PartnersThe Crypto That’s Making Wall Street SweatThe Crypto Wall Street Is Desperate to Hide It's happening now, right under everyone's radar. Big tech gian...Crypto 101 Media | SponsoredMissed Nvidia? Watch this ASAPThis little-known project that Bill Gates has been quietly working on that’s about to unleash an AI breakthrou...Brownstone Research | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | Sponsored24/7 Automated Profits in CryptoWhat if you could make consistent daily profits in crypto with minimal effort? Beyond trading lies a vast w...Crypto Swap Profits | SponsoredCrypto’s next big bull run?Juan Villaverde may be America’s top crypto expert. And he says something big is coming for crypto – on Nov...Weiss Ratings | Sponsored“This Changes Everything” - Trump Hands Millions Massive IRS GiftNow it's your time to return the favor by taking advantage of this tax "revenge loophole." Because even as ...Colonial Metals | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredUnveiled: NVIDIA’s "Secret Royalty" ProgramDid you know that there's an investment that will give you the opportunity to collect "royalties" every time N...Behind the Markets | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding ALX Oncology Holdings Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share ALX Oncology With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free ALXO Stock Alerts